{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Medifast, Inc. Experiences Revision in Its Stock Evaluation Amidst Financial Challenges
Medifast, Inc. has experienced a valuation adjustment amid challenging financial metrics, including a negative return on equity and significant operational hurdles. Compared to peers, its valuation ratios highlight broader industry difficulties. Year-to-date returns are down substantially, reflecting competitive pressures and operational challenges in the current market environment.
Medifast, Inc. Experiences Valuation Adjustment Amidst Challenging Market Conditions
Medifast, Inc. has recently adjusted its valuation amid ongoing financial challenges, with a notable decline in its annual return. Key metrics indicate a low price-to-book value and negative performance indicators. Compared to peers, Medifast's valuation appears more favorable, suggesting a complex industry positioning for investors to consider.
Is Medifast, Inc. technically bullish or bearish?
As of September 2, 2025, Medifast, Inc. shows a mildly bearish technical trend, with daily moving averages indicating bearishness despite some positive momentum from weekly and monthly MACD indicators, and it has significantly underperformed the S&P 500 year-to-date and over the past year.
Is Medifast, Inc. overvalued or undervalued?
As of August 7, 2025, Medifast, Inc. is considered undervalued with a valuation grade shift to attractive, despite negative earnings metrics and a year-to-date return of -17.31%, compared to the S&P 500's 12.22%, while its Price to Book Value is 0.66 and EV to EBIT ratio is 2.98, indicating relative attractiveness against peers with lower P/E ratios.
Is Medifast, Inc. overvalued or undervalued?
As of April 28, 2025, Medifast, Inc. is considered risky and overvalued due to a P/E ratio of NA from losses, a Price to Book Value of 0.66, an EV to EBIT of 2.98, and a negative ROE of -0.84%, while its year-to-date return of -24.46% significantly underperforms the S&P 500's 2.44% gain.
Is Medifast, Inc. technically bullish or bearish?
As of June 18, 2025, the trend is mildly bullish based on weekly and monthly indicators, but mixed signals from daily moving averages and Bollinger Bands suggest caution due to overall negative performance compared to the S&P 500.
Who are in the management team of Medifast, Inc.?
As of March 2022, the management team of Medifast, Inc. includes Executive Chairman and CEO Daniel Chard, Lead Independent Director Jeffrey Brown, and Independent Directors Kevin Byrnes, Constance Hallquist, Michael Hoer, and Scott Schlackman. They are responsible for the company's strategic direction and governance.
What does Medifast, Inc. do?
Medifast, Inc. produces and sells weight loss and healthy living products, operating in the micro-cap market with a recent net sales of $116 million and a net profit of -$1 million. The company has a market cap of $148.27 million and does not pay dividends.
How big is Medifast, Inc.?
As of Jun 18, Medifast, Inc. has a market capitalization of 148.27 million and reported net sales of 543.45 million with a net profit of -6.99 million over the latest four quarters. Shareholder's funds total 210.11 million, and total assets are 293.23 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
